Here, we present some current therapies and examples of drugs with their mechanisms of action and known challenges or failures: monoclonal antibodies targeting amyloid beta or tau (e.g., aducanumab for Alzheimer’s disease) aim to clear amyloid-beta plaques or tau aggregates (Zhang et al., 2023). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.